Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose Escalation, Safety, and Immunogenicity Trial of an Alphavirus Replicon HIV-1 Subtype C Gag Vaccine (AVX101) in Healthy HIV-1 Uninfected Adult Participants

NCT00097838 is registered in ClinicalTrials.gov with AlphaVax, Inc. as lead sponsor.

NCT NCT00097838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00097838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose Escalation, Safety, and Immunogenicity Trial of an Alphavirus Replicon HIV-1 Subtype C Gag Vaccine (AVX101) in Healthy HIV-1 Uninfected Adult Participants
Lead sponsor
AlphaVax, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2004
Completion date
September 30, 2009
Enrollment
96 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections